tetano
Editor, Senior Moderator
Clin Exp Vaccine Res
. 2024 Apr;13(2):166-170.
doi: 10.7774/cevr.2024.13.2.166. Epub 2024 Apr 30. Henoch-Schönlein purpura following mRNA COVID-19 vaccination: a case report
Mi-Ok Lee[SUP] 1 [/SUP], Seok-Ju Yoo[SUP] 2 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) vaccine was developed to provide immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in 2019. The vaccine has proven to be effective in reducing severity and mortality and preventing infection. Henoch-Schönlein purpura is an autoimmune vasculitis (immunoglobulin A vasculitis). Historically, vaccines have been administered primarily to children, and Henoch-Schönlein purpura has often been reported in children following vaccination. However, since the start of COVID-19 vaccination, an increasing number of cases have been reported in adults. Here, we report a case of a patient who developed hematuria and proteinuria after receiving the messenger RNA COVID-19 vaccine. A 22-year-old man presented to the hospital with a lower extremity rash, bilateral ankle pain, and abdominal pain 18 days after receiving the COVID-19 vaccine. The man had no significant medical history and was not taking any medications. Laboratory tests showed normal platelet counts but elevated white blood cell counts and C-reactive protein and fibrinogen levels. He was treated with the non-steroidal anti-inflammatory drugs, pheniramine and prednisolone. At 40 days after starting treatment, C-reactive protein levels were within normal limits, and no hematuria was observed. Treatment was terminated when the purpura disappeared. This report is intended to highlight the need for further research to be proactive and carefully monitor for conditions associated with the COVID-19 vaccine.
Keywords: COVID-19 vaccines; Case reports; Henoch-Schönlein purpura; IgA vasculitis; mRNA vaccine; mRNA-1273 vaccine.
. 2024 Apr;13(2):166-170.
doi: 10.7774/cevr.2024.13.2.166. Epub 2024 Apr 30. Henoch-Schönlein purpura following mRNA COVID-19 vaccination: a case report
Mi-Ok Lee[SUP] 1 [/SUP], Seok-Ju Yoo[SUP] 2 [/SUP]
Affiliations
- PMID: 38752010
- PMCID: PMC11091430
- DOI: 10.7774/cevr.2024.13.2.166
The coronavirus disease 2019 (COVID-19) vaccine was developed to provide immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in 2019. The vaccine has proven to be effective in reducing severity and mortality and preventing infection. Henoch-Schönlein purpura is an autoimmune vasculitis (immunoglobulin A vasculitis). Historically, vaccines have been administered primarily to children, and Henoch-Schönlein purpura has often been reported in children following vaccination. However, since the start of COVID-19 vaccination, an increasing number of cases have been reported in adults. Here, we report a case of a patient who developed hematuria and proteinuria after receiving the messenger RNA COVID-19 vaccine. A 22-year-old man presented to the hospital with a lower extremity rash, bilateral ankle pain, and abdominal pain 18 days after receiving the COVID-19 vaccine. The man had no significant medical history and was not taking any medications. Laboratory tests showed normal platelet counts but elevated white blood cell counts and C-reactive protein and fibrinogen levels. He was treated with the non-steroidal anti-inflammatory drugs, pheniramine and prednisolone. At 40 days after starting treatment, C-reactive protein levels were within normal limits, and no hematuria was observed. Treatment was terminated when the purpura disappeared. This report is intended to highlight the need for further research to be proactive and carefully monitor for conditions associated with the COVID-19 vaccine.
Keywords: COVID-19 vaccines; Case reports; Henoch-Schönlein purpura; IgA vasculitis; mRNA vaccine; mRNA-1273 vaccine.